Viridian Therapeutics, Inc. (VRDN)
| Market Cap | 1.18B |
| Revenue (ttm) | 302,000 |
| Net Income (ttm) | -208.56M |
| Shares Out | 81.48M |
| EPS (ttm) | -3.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,107 |
| Open | 14.67 |
| Previous Close | 14.67 |
| Day's Range | 14.20 - 14.74 |
| 52-Week Range | 11.40 - 27.20 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 36.44 (+152.36%) |
| Earnings Date | May 7, 2025 |
About VRDN
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is... [Read more]
Financial Performance
In 2024, Viridian Therapeutics's revenue was $302,000, a decrease of -3.82% compared to the previous year's $314,000. Losses were -$208.56 million, 19.2% more than in 2023.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $36.44, which is an increase of 152.36% from the latest price.
News
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window
Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing...
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to T...
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved th...
Viridian Therapeutics' eye disorder drug meets late-stage study goal
Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian Therapeutics' Superior Prospects Make It A Buy
Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 a...
3 Small Biotech Stocks With The 'Big Mo' Right Now
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong mome...
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for TH...
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study
Viridian Therapeutics said on Tuesday its experimental drug to treat patients with thyroid eye disease significantly reduced bulging of the eye in a late-stage study.
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Top 3 Health Care Stocks You May Want To Dump This Quarter
As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
3 Biotech Names With Potential Catalysts By Year End
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should con...
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRI...
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...